Optimization of Standard Treatment in AML
Session III of iwAL 2018 saw experts present on enhancing standard treatments in AML. Presenters Klaus Metzeler, MD, Wolfgang Hiddemann, MD, PhD, and Alan Burnett, MD, FRCP, discuss various aspects of this subject, including adverse genetic features, post-remission therapy, novel therapies, and low-intensity treatments in the elderly. The question of how to best treat APL moving forward was raised by Laura Cicconi, MD.
Presentations
LMU-University Hospital Munich, Munich, Germany
Klaus Metzeler, MD, LMU-University Hospital Munich, Munich, Germany, discusses adverse genetic features in AML.
LMU-University Hospital Munich, Munich, Germany
Wolfgang Hiddemann, MD, PhD, LMU-University Hospital Munich, Munich, Germany, presents therapy options for patients post-remission.
Cardiff University, Cardiff, UK
Alan Burnett, MD, FRCP, from Cardiff University, Cardiff, UK, delivers a talk on new drugs and low-intensity treatments for older patients with AML.
University of Rome Tor Vergata, Rome, Italy
Laura Cicconi, MD, from the University of Rome Tor Vergata, Rome, Italy, discusses treatment options for APL.
